Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CGON

Cg Oncology Inc.

Sep 27 • 04:00PM ET

37.87

Dollar change +1.09
Percentage change 2.96	%

Healthcare • Biotechnology • USA • NASD

Held by: IWM XBI VTI VB VBR VXF IWO SCHA IWN VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	40.02%	Shs Outstand	66.64M	Perf Week	-2.90%
Market Cap	2.54B	Forward P/E	-	EPS next Y	-1.77	Insider Trans	-2.37%	Shs Float	40.23M	Perf Month	2.94%
Income	-	PEG	-	EPS next Q	-0.38	Inst Own	47.97%	Short Float	15.08%	Perf Quarter	19.96%
Sales	-	P/S	-	EPS this Y	-26.33%	Inst Trans	-	Short Ratio	8.18	Perf Half Y	-13.74%
Book/sh	8.29	P/B	4.57	EPS next Y	-24.71%	ROA	-	Short Interest	6.06M	Perf Year	-
Cash/sh	8.24	P/C	4.59	EPS next 5Y	-	ROE	-	52W Range	25.77 - 50.23	Perf YTD	1.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-24.61%	Beta	-
Dividend TTM	-	Quick Ratio	47.57	Sales past 5Y	-45.67%	Gross Margin	-	52W Low	46.95%	ATR (14)	1.91
Dividend Ex-Date	-	Current Ratio	47.57	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	55.22	Volatility	4.12% 5.50%
Employees	61	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	67.38
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-55.40%	Payout	-	Rel Volume	0.72	Prev Close	36.78
Sales Surprise	-47.07%	EPS Surprise	21.35%	Sales Q/Q	-	Earnings	Aug 08 BMO	Avg Volume	740.99K	Price	37.87
SMA20	2.49%	SMA50	7.41%	SMA200	4.01%	Trades		Volume	530,852	Change	2.96%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-24	Initiated	RBC Capital Mkts	Outperform	$66
Aug-28-24	Initiated	ROTH MKM	Buy	$65
Jun-28-24	Initiated	BofA Securities	Buy	$65
Feb-20-24	Initiated	Morgan Stanley	Overweight	$55
Feb-20-24	Initiated	Goldman	Neutral	$42
Feb-20-24	Initiated	Cantor Fitzgerald	Overweight	$75
Feb-14-24	Initiated	H.C. Wainwright	Buy	$75

Sep-14-24 05:25PM	Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Aug-30-24 08:00AM	CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-08-24 08:23AM	CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +7.02%
Jun-18-24 08:00AM	CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec (GlobeNewswire)
Jun-06-24 12:14PM	CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC (GlobeNewswire)
08:00AM	Loading…
May-24-24 08:00AM	CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting (GlobeNewswire) +9.07%
May-11-24 10:16AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 01:54PM	CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024 (InvestorPlace) -7.43%
08:00AM	CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-03-24 11:23AM	Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire) -8.18%
Apr-26-24 08:00AM	CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 (GlobeNewswire) +13.26%
Apr-24-24 10:00AM	CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 (GlobeNewswire)
Apr-11-24 10:02PM	20 Countries with the Most Domestically Listed Companies in the World (Insider Monkey)
Mar-28-24 08:00AM	CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting (GlobeNewswire) +7.07%
Feb-27-24 08:00AM	CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
07:00AM	Loading…
Jan-30-24 07:00AM	CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
Jan-26-24 04:20PM	In Bad News for IPO Market, BrightSpring Closes Below Offering Price (The Wall Street Journal) -5.76% +5.62%
Jan-24-24 07:10PM	CG Oncology Announces Pricing of Upsized Initial Public Offering (Business Wire)

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Song Hong Fang	Director	Aug 29 '24	Sale	35.36	650,455	23,000,089	586,982	Aug 30 07:18 PM
Unique Diamond Investments Ltd	Director	Aug 29 '24	Proposed Sale	35.36	424,210	15,000,000		Aug 29 08:27 PM
Charming Jade Ltd	Director	Aug 29 '24	Proposed Sale	35.36	226,245	8,000,000		Aug 29 08:26 PM
Unique Diamond Investments Ltd	Director	Aug 29 '24	Proposed Sale	35.36	424,210	15,000,000		Aug 29 06:44 PM
Charming Jade Ltd	Director	Aug 29 '24	Proposed Sale	35.36	226,245	8,000,000		Aug 29 06:43 PM
Kasturi Vijay	Chief Medical Officer	Jan 29 '24	Buy	19.00	1,315	24,985	1,315	Jan 31 04:30 PM
Roche Corleen M.	CFO & Secretary	Jan 29 '24	Buy	19.00	2,000	38,000	2,000	Jan 31 04:30 PM
Song Hong Fang	Director	Jan 29 '24	Buy	19.00	263,157	4,999,983	613,928	Jan 31 04:30 PM
Decheng Capital Global Life Sc	10% Owner	Jan 29 '24	Buy	19.00	400,000	7,600,000	400,000	Jan 31 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGON

Cg Oncology Inc.

Upgrade your FINVIZ experience